- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of December 30
The Center for Biosimilars® recaps the top stories for the week of December 30, 2019.
Transcript
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 30, 2019.
Number 5: A recent study concluded that, for patients who experienced side effects or a loss of response after switching to biosimilar infliximab, a switch back to the reference product was effective.
Number 4: Anti—tumor necrosis factor therapies could play a role in alleviating or even preventing some adverse events related to immune checkpoint inhibition.
Number 3: Recent research shows that many US patients with rheumatoid arthritis who do not respond well to conventional drugs are not advancing to biologic treatment.
Number 2: Clover Biopharmaceuticals announced this week that it has dosed the first patient in a phase 3 clinical study of a proposed etanercept biosimilar.
Number 1: An official working group of the Swiss Society of Gastroenterology has issued a new position statement on the use of biosimilars in treating inflammatory bowel disease.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
